KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $589.2 million.

  • Royalty Pharma's Shares Outstanding (Weighted Average) fell 1.73% to $583.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $583.2 million, marking a year-over-year decrease of 1.73%. This contributed to the annual value of $589.2 million for FY2024, which is 1.38% down from last year.
  • Latest data reveals that Royalty Pharma reported Shares Outstanding (Weighted Average) of $589.2 million as of FY2024, which was down 1.38% from $597.4 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) registered a high of $607.2 million during FY2022, and its lowest value of $589.2 million during FY2024.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $597.4 million (2023), whereas its average is $597.9 million.
  • In the last 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) increased by 1.97% in 2020 and then decreased by 1.61% in 2023.
  • Over the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) (Yearly) stood at $607.1 million in 2020, then climbed by 0.01% to $607.2 million in 2021, then climbed by 0.01% to $607.2 million in 2022, then dropped by 1.61% to $597.4 million in 2023, then decreased by 1.38% to $589.2 million in 2024.